Beyondspring Inc (BYSI)
NASDAQ:BYSI
BYSI Stock Chart & Stats
$1.66
-$0.09(-5.17%)
At close: 4:00 PM EST
$1.66
-$0.09(-5.17%)
Day’s Range― - ―
52-Week Range$1.03 - $3.44
Previous CloseN/A
Volume3.10K
Average Volume (3M)478.07K
Market Cap
$71.55M
Enterprise Value$64.09M
Total Cash (Recent Filing)$12.56M
Total Debt (Recent Filing)$320.00K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Jun 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding41,119,820
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.49K
Enterprise Value/Ebitda-7.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Bulls Say, Bears Say
Bulls Say
Late-stage Positive Phase 3 Survival DataStatistically significant overall survival benefit in a Phase 3 cohort materially de-risks Plinabulin’s clinical profile. Durable survival data published/presented at major congresses supports regulatory discussions and strengthens the long-term commercial case versus earlier-stage assets.
Distinct, First-in-class MechanismA unique dendritic-cell maturation mechanism creates a structural competitive advantage: differentiation from cytotoxic or checkpoint agents increases combination utility, supports label breadth across resistant NSCLC populations, and can sustain durable clinical and commercial positioning.
Safety Profile Improves Chemotherapy TolerabilityConsistent reductions in severe neutropenia strengthen the drug’s value proposition by enabling longer, more effective chemotherapy exposure. This safety-driven clinical utility supports durable adoption by oncologists and payers if confirmed in registrational settings.
Bears Say
Pre-commercial With Negligible RevenueThe company remains pre-commercial with effectively zero revenue, leaving long-term viability dependent on successful regulatory approval and commercialization. Absent product sales, the firm lacks operating cash generation and must rely on external financing or partner deals.
Negative Shareholder Equity And Shrinking Asset BaseSustained negative shareholder equity and a large decline in assets reflect cumulative cash consumption and weaken financial flexibility. This structural balance-sheet weakness increases dilution and refinancing risk and constrains strategic choices for long-term development and commercialization.
Persistent Operating Cash BurnConsistently negative operating cash flow indicates reliance on external funding to sustain development. Even with improved loss trends, ongoing burn creates material funding risk, which can delay programs, force unfavorable financings, or necessitate asset sales absent partnerships or milestones.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $1.03 and its highest was $3.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $71.55M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is Jun 11, 2026 which is in 60 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on Mar 25, 2026. The company reported -$0.053 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.053.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.053 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beyondspring Stock Smart Score
Company Description
Beyondspring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Technical Analysis
Plus Therapeutics
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Ownership Overview
9.80% Insiders
2.07% Mutual Funds
9.34% Other Institutional Investors
77.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---